Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.

@article{Gotoh2000CilostazolSP,
  title={Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction.},
  author={Fumio Gotoh and Hideo Tohgi and Shinji Hirai and Akiro Terashi and Yasuo Fukuuchi and Eiichi Otomo and Yoko Shinohara and Eisaku Itoh and Taiji Matsuda and Takahisa Sawada and Takuhiro Yamaguchi and Katsuya Nishimaru and Yasuo Ohashi},
  journal={Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association},
  year={2000},
  volume={9 4},
  pages={147-57}
}
Cilostazol, an antiplatelet drug that increases the cyclic adenosine monophosphate (AMP) levels in platelets via inhibition of cyclic AMP phosphodiesterase, has been used in chronic arterial occlusive disease. The purpose of the present study was to examine the effects of cilostazol on the recurrence of cerebral infarction using a multicenter, randomized, placebo-controlled, double-blind clinical trial method. Patients who suffered from cerebral infarction at 1 to 6 months before the trial were… CONTINUE READING